Aligos’s MASH Data Look Competitive, But Path Forward Is Unclear

Aligos’s THRβ agonist yielded hepatic fat reduction equal to or better than its class, but the biotech prefers moving forward with a partner. Hepatitis B may be the firm’s higher priority.